Token-Mol 1.0: tokenized drug design with large language models.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 40360500.
- Also identified by DOI 10.1038/s41467-025-59628-y and PMC identifier 12075800.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The integration of large language models (LLMs) into drug design is gaining momentum; however, existing approaches often struggle to effectively incorporate three-dimensional molecular structures. Here, we present Token-Mol, a token-only 3D drug design model that encodes both 2D and 3D structural information, along with molecular properties, into discrete tokens. Built on a transformer decoder and trained with causal masking, Token-Mol introduces a Gaussian cross-entropy loss function tailored for regression tasks, enabling superior performance across multiple downstream applications. The model surpasses existing methods, improving molecular conformation generation by over 10% and 20% across two datasets, while outperforming token-only models by 30% in property prediction. In pocket-based molecular generation, it enhances drug-likeness and synthetic accessibility by approximately 11% and 14%, respectively. Notably, Token-Mol operates 35 times faster than expert diffusion models. In real-world validation, it improves success rates and, when combined with reinforcement learning, further optimizes affinity and drug-likeness, advancing AI-driven drug discovery.
Medical subject headings
- Drug Design